You are here

Savient

New CEO = Dendreon Takeover Target?

Motley Fool

Thu, 02/2/12 - 10:09 am

Savient's Krystexxa: How I Get A $209 Million Sales Estimate By 2015

Seeking Alpha

Thu, 12/8/11 - 11:33 am

Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity

Seeking Alpha

Wed, 11/30/11 - 05:29 pm

Savient Pharmaceuticals down3.9%

Zacks

Sat, 11/19/11 - 01:16 pm

Savient falls after analyst downgrades stock, expecting lower sales of its gout drug Krystexxa

Yahoo/AP

Fri, 11/11/11 - 09:50 am

Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting

Yahoo/PR NewsWire

Sat, 11/5/11 - 02:49 pm

New Medicare code could boost Krystexxa sales

Fierce Pharma

Fri, 11/4/11 - 12:19 pm

Biotech Investors Bow Out as Hurdles Grow

Bloomberg

Thu, 09/29/11 - 09:06 am

Human Genome Sciences

Biotech Busts And Breakthroughs For August

Forbes

Thu, 09/1/11 - 11:34 am

Pacific Biosciences

Human Genome Sciences

3 biotech stocks battle the ‘Dendreon Effect’ - Company’s troubles with Provenge chill fellow drug makers

Marketwatch

Fri, 08/19/11 - 09:20 am

Human Genome Sciences

Vertex Pharmaceuticals

Seattle Genetics

Dendreon's Blowup Spreads Across Biotech

TheStreet.com

Thu, 08/4/11 - 10:57 am

Human Genome Sciences

Seattle Genetics

Calls Purchased on Savient Pharmaceuticals

Benzinga

Sat, 07/30/11 - 10:13 am

7 Biotechs Near 52-Week Lows

Motley Fool

Tue, 07/19/11 - 06:29 pm

Human Genome Sciences

Isis Pharmaceuticals

Protalix BioTherapeutics

5 Biotech Takeover / LBO Targets With Bullish Short Trends

Seeking Alpha

Sat, 07/16/11 - 11:39 am

Acorda Therapeutics

4 Biotech Stocks That Could Pop

Seeking Alpha

Thu, 05/19/11 - 02:05 pm

Amag Pharmaceuticals

Savient Pharma: Cheap Biotech Without FDA Approval Risk

Seeking Alpha

Tue, 04/26/11 - 06:18 am

Top 15 Most Undervalued Biotech Stocks By Analyst Target Price

Seeking Alpha

Sat, 04/9/11 - 11:02 am

Lexicon Pharmaceuticals

Human Genome Sciences

Cadence Pharmaceuticals

ONYX Pharmaceuticals

Emergent BioSolutions

Spectrum Pharmaceuticals

Top Biotech Takeout Targets in 2011

Minyanville

Fri, 02/18/11 - 03:32 pm

Seattle Genetics

Vertex Pharmaceuticals

Lexicon Pharmaceuticals

Savient Closes Sale of $230 Million in Convertible Senior Notes

Yahoo/PR NewsWire

Sat, 02/5/11 - 10:51 am

Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes

Yahoo/PR NewsWire

Mon, 01/31/11 - 07:51 am

Pages